Skip to main content

Military Health System

DOD participates in new COVID-19 antibody combination prevention trial

Image of Woman gets blood drawn. Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

Naval Medical Research Center Joint Study with Mount Sinai Uncovers Differences in COVID-19 Immune Response between the Sexes

Article Around MHS
12/5/2022
Amanda Cherry, research assistant, performing diagnostic testing at NMRC

A collaborative study between researchers at Naval Medical Research Center and the Icahn School of Medicine at Mount Sinai, and Princeton University has highlighted immune response differences in the coronavirus infection responses between male and female patients.

Recommended Content:

Medical Research and Development | Coronavirus & the MHS Response | Coronavirus

Get Protected With New COVID-19 Booster and Flu Vaccine

Article Around MHS
10/24/2022
Military medical personnel administering vaccine

There are two vaccines you should consider getting this Fall, and now you can get them both at the same time.

Recommended Content:

Immunizations | COVID-19 Vaccine Efforts | Seasonal Influenza Vaccine Toolkit | Coronavirus and the COVID-19 Vaccine

Collaborating In the ER: Reservists Assist, Learn in Community Hospitals

Article Around MHS
10/20/2022
Military medical personnel in medical training session

In the early days of the COVID-19 pandemic–when there were no vaccines, a shortage of health care workers, and hospitals were beyond capacity– the U.S. health care system needed help. Here's one of many ways the Department of Defense answered the call.

Recommended Content:

Coronavirus & the MHS Response

Time to Get Your Flu Shot and Your COVID-19 Booster, Too

Article
10/14/2022
Senior MHS officials and medics from the Pentagon stand together Oct. 13 after receiving their flu shots and bivalent COVID-19 boosters.."

It's flu shot time. Get your COVID-19 booster at the same time.

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | Coronavirus and the COVID-19 Vaccine | Seasonal Influenza Vaccine Toolkit | Immunizations | Coronavirus

Prevent the Spread of Influenza and COVID-19 Viruses Within Your Community

Article
10/11/2022
A person getting an injection on their arm.

As families return from summer vacation and students return to school, the influenza (flu) season is approaching while the COVID-19 pandemic is still on-going.

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | Immunizations | Coronavirus and the COVID-19 Vaccine | Seasonal Influenza Vaccine Toolkit

DHA Form 207: COVID-19 Vaccine Screening and Immunization Document v22

Form/Template
9/9/2022

The purpose of this form is to determine if the COVID-19 vaccine can be administered to the patient. (v22, Sept. 2022)

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Immunization Healthcare Division | COVID-19 Vaccine Efforts | COVID-19 Information for Military Treatment Facility Directors | Coronavirus

Ramstein Now Offers Novavax Vaccine

Article Around MHS
9/8/2022
Military medical gives Soldier a COVID-19 vaccine

The 86th Medical Group is now offering the Novavax COVID-19 vaccine, which has been authorized for emergency use by the U.S. Food and Drug Administration, to members 18 years and older in the Kaiserslautern Military Community.

Recommended Content:

Immunization Healthcare Division | COVID-19 Vaccine Efforts | Immunizations | Coronavirus

Novavax COVID-19 Vaccine Now Available for 12 to 17 Year-Olds

Article
8/30/2022
Air Force Staff. Sgt. fills a syringe with a COVID-19 vaccine at Ramstein Air Base, Germany.

Novavax COVID-19 Vaccine is Available for Those 12 Years' Old and Above

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts

New COVID-19 Boosters Against Subvariants Coming Soon

Article
8/29/2022
Marine on right gets a COVID-19 booster vaccination from a nursing student on his left.

Brooklyn Marine gets COVID-19 booster vaccination.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts

Consolidated Department of Defense Coronavirus Disease 2019 Force Health Protection Guidance

Policy

Consolidates and updates the Department’s guidance regarding vaccination verification, vaccination status, COVID-19 testing, surveillance and screening testing, personnel protection on-site mask requirements, (e.g., DHA military medical treatment facilities, meetings, travel), and the protection of personally identifiable information.

COVID-19 Moderna Vaccine

Publication
8/17/2022

Moderna and mRNA vaccines are available. Moderna includes two doses, 28 days apart.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Get to Know the COVID-19 Vaccines | Types of COVID-19 Vaccines | Coronavirus & the MHS Response

COVID-19 Pfizer Vaccine

Publication
8/17/2022

Pfizer mRNA vaccines are available. Pfizer includes two doses, 21 days apart.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Get to Know the COVID-19 Vaccines | Types of COVID-19 Vaccines | Coronavirus & the MHS Response

COVID-19 Moderna and Pfizer Vaccines

Publication
8/17/2022

Moderna and Pfizer mRNA vaccines are available. Moderna includes two doses, 28 days apart. Pfizer includes two doses, 21 days apart. Remember to mark your calendar and schedule time for your second dose

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Get to Know the COVID-19 Vaccines | Types of COVID-19 Vaccines | Coronavirus & the MHS Response

Learn the Most Recent Age Requirements for COVID-19 Vaccines and Boosters

Article
8/10/2022
A man fist bumps a child.

The best way to prevent the spread of COVID-19 is to get your vaccines and booster shots.

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

Telemedicine Privilege by Proxy Expands Access to MHS Care

Article
8/10/2022
Infographic featuring Lt Col Legault

MHS has Telemedicine Privilege by Proxy: A fast, efficient process that enables providers to file one application and get permission to virtually treat patients anywhere in the MHS.

Recommended Content:

Coronavirus & the MHS Response | Telehealth Program
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 25
Refine your search
Last Updated: September 27, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery